Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects . In Vitro Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP). Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2. In Vivo Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone. Form:Solid